Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Namwiwat Medical PCLBKK:NAM 35 Debt-to-Equity is 0.24 as of Mar. 2026, which is 9% above its 10-year median of 0.22. GuruFocus rates BKK:NAM with a GF Score™ of 35/100 and a GF Value™ of ฿5.87 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 699 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks worse than 50.93% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Namwiwat Medical PCL's Debt-to-Equity or its related term are showing as below:
BKK:NAM'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.22 Max: 1.7
Current: 0.24
During the past 6 years, the highest Debt-to-Equity Ratio of Namwiwat Medical PCL was 1.70. The lowest was 0.09. And the median was 0.22.
BKK:NAM's Debt-to-Equity is ranked worse than 50.93% of 699
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs BKK:NAM: 0.24
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Namwiwat Medical PCL Debt-to-Equity Related Terms
Namwiwat Medical PCL Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Namwiwat Medical PCL's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:NAM vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Namwiwat Medical PCL's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Namwiwat Medical PCL Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Namwiwat Medical PCL's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Namwiwat Medical PCL (BKK:NAM) has a Debt-to-Equity of 0.24 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Namwiwat Medical PCL and its competitors. This is near median its historical median of 0.22. Over the past decade, Namwiwat Medical PCL's Debt-to-Equity has ranged from 0.09 to 1.70. According to the industry distribution chart, Namwiwat Medical PCL ranks #356 out of 699 companies in the Medical Devices & Instruments industry, placing it in the top 50.9%.
Is Namwiwat Medical PCL's Debt-to-Equity too high?
Namwiwat Medical PCL's current Debt-to-Equity of 0.24 is near median its 10-year median of 0.22. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 1.70. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Namwiwat Medical PCL's value of 0.24 is 4.3% above this industry median. Based on the distribution chart, Namwiwat Medical PCL ranks #356 out of 699 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Namwiwat Medical PCL has a GF Score™ of 35/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #356 out of 699 companies for Debt-to-Equity. This places Namwiwat Medical PCL in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Namwiwat Medical PCL's value of 0.24 is 4.3% above this benchmark. Historically, Namwiwat Medical PCL's own Debt-to-Equity has ranged from 0.09 to 1.70 over the past decade. While the company's 10-year median is 0.22 vs. the industry median of 0.23, Namwiwat Medical PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Namwiwat Medical PCL's current Debt-to-Equity of 0.24 is 4.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Namwiwat Medical PCL and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current Debt-to-Equity is 0.24, which is near median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿5.87, compared to a current price of ฿3.30 — trading 43.8% below its estimated fair value. The current Debt-to-Equity is 0.24, which is near median its 10-year median of 0.22 and 4.3% above the Medical Devices & Instruments industry median of 0.23. Namwiwat Medical PCL's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current Debt-to-Equity is 0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?
Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued.
The current stock price of ฿3.30 is trading 43.8% below its estimated GF Value™ of ฿5.87.
GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.
Key valuation signals for BKK:NAM:
Debt-to-Equity: 0.24 (near median its 10-year median of 0.22)
GF Value™: ฿5.87 vs. price of ฿3.30 (43.8% below fair value)
Industry Position: 4.3% above the Medical Devices & Instruments median (#356 of 699)
No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
35GF Score
Get the complete analysis for BKK:NAM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NAM has been successfully added to your 
